PharmExec

Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary ...
PharmExec

HHS Secretary of Health RFK Jr. Revises Agency’s Leadership Team: Report

HHS Secretary Robert F. Kennedy Jr. reorganized senior leadership at the department to streamline management and advance the ...
PharmExec

FDA Approves Monthly Dosing Schedule for Rybrevant Faspro

FDA approved a simplified, once-monthly dosing schedule for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) when used in combination with Lazcluze (lazertinib) as a first-line treatment for ...
PharmExec

Delivering Actual Value: Q&A with Sandy Tammisetty

Sandy Tammisetty, VP of Veeva Services Practive Group at Conexus Solutions, spoke with Pharmaceutical Executive about where AI implementation is working for the pharma industry, and where it doesn’t ...
PharmExec

Complex Challenges Arising from Pricing Reforms: Q&A with Jesse Mendelsohn

Pharmaceutical Executive recently spoke with Jesse Mendelsohn, SVP at Model N, about the complications that can arise from companies entering into drug pricing agreements with the government. This ...
PharmExec

You Can Just (Not) Do Stuff: FDA’s Power to De-Bottleneck Early-Stage Clinical Trials

What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...